Indications

Inflammatory Bowel Disease: Crohn's disease (CD), ulcerative colitis (UC).

Target Patients

Offers a novel, revolutionary oral biologic therapy for patients with inadequate response to conventional therapies or existing biologics, or those intolerant to injection-based treatments.

Mechanism of Action

Precise Blockade: Neutralizes TL1A, reducing the differentiation and activation of Th1/Th17 cells, thereby disrupting downstream pathogenic signaling pathways.

Source Regulation: The nanobody can be administered orally, directly reaching intestinal tissues to neutralize TL1A at the source. This alleviates abnormal immune responses and inflammatory damage in the intestinal mucosa, promoting tissue repair.

Administration

Route: Oral.

Frequency: Once-daily or twice-daily dosing, as per clinical protocol design.

Key Advantages

Oral Stability: Leveraging the unique stability, acid-resistance, and enzyme-resistance of the nanobody structure, this product overcomes the harsh gastrointestinal environment, maintains structural integrity, and achieves efficient intestinal absorption and targeted delivery.

Enhanced Safety: Oral administration enables higher drug exposure concentrations in the intestine even at lower doses. It also avoids the systemic drug exposure associated with traditional large-molecule delivery methods, achieving a superior safety profile.

Treatment Convenience: As the world's leading oral anti-TL1A nanobody, this product completely eliminates the pain, inconvenience, and dependence on medical resources associated with injections, making it an ideal choice for long-term disease management.